Getinge AB stock (SE0000202624): focus on hospital demand after latest quarterly figures

Medical technology group Getinge AB has recently reported quarterly results and updated investors on demand trends in intensive care and surgical products. What the latest numbers mean for the Swedish stock and why the company remains relevant for US-focused healthcare portfolios.

Getinge AB, the Swedish medical technology group best known for hospital and intensive care equipment, has recently updated the market with new quarterly figures and comments on demand trends in key product areas. The company reported its latest financial results and business developments in late April 2025, including sales performance in different regions and product segments, according to a company release published on the investor relations website at the time (Getinge investor information as of 04/23/2025). For investors who follow global healthcare suppliers listed in Europe but with international reach, the stock offers insights into hospital spending cycles and capital equipment budgets.

In those quarterly figures, Getinge highlighted revenue trends in its acute care therapies, surgical workflows and life science units, as well as profitability metrics such as earnings before interest and taxes for the period, all in connection with the same release and presentations published in April 2025 (Getinge news overview as of 04/23/2025). While exact segment numbers can vary between quarters, the report underlined that demand from hospitals and healthcare systems continues to be shaped by procedure volumes, reimbursement conditions and public investment programs.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Getinge B
• Sector/industry: Medical technology, hospital equipment
• Headquarters/country: Gothenburg, Sweden
• Core markets: Europe, North America, selected Asia-Pacific and emerging markets
• Key revenue drivers: Intensive care ventilators, heart-lung machines, surgical workflow solutions, infection control equipment and related services
• Home exchange/listing venue: Nasdaq Stockholm (class B shares)
• Trading currency: Swedish krona (SEK)

Getinge AB: core business model

Getinge AB is positioned as a global supplier of products and solutions that are critical for modern hospitals, intensive care units and life science laboratories. The group typically structures its operations into areas such as acute care therapies, surgical workflows and life science, each targeting different steps along the patient treatment and care pathway. This setup allows the company to sell both high-value capital equipment and recurring consumables or services, which can make revenue streams more resilient over time, according to the company’s own business description on its website (Getinge corporate profile as of 02/10/2025).

In acute care therapies, Getinge focuses on equipment and therapies used in intensive care, cardiology and related fields. Typical products include ventilators, hemodynamic monitoring systems and devices used in cardiopulmonary bypass. These products are often mission-critical for hospitals, because they support patients with life-threatening conditions, including respiratory failure or during complex cardiac surgery. As a result, hospitals usually place a high priority on reliability, regulatory compliance and service support when choosing suppliers, and Getinge positions itself as a long-term partner rather than a pure hardware vendor, based on the positioning in its annual reports and strategy descriptions released in 2024 (Getinge annual report information as of 03/20/2024).

The surgical workflows segment deals with operating room integration, sterile supply management and infection control. In practice, this includes operating tables, lights, modular OR infrastructure, sterilizers and washer-disinfectors, as well as software tools that help hospitals manage instrument flows and documentation. These systems are usually sold as part of larger projects, such as the construction or modernization of operating rooms and central sterile service departments. Because such projects involve long planning cycles and significant capital expenditure, Getinge’s sales teams typically work closely with hospital planners and construction partners over extended periods, making project management and long-term customer relationships an important element of the business.

The life science unit targets universities, research institutions, biopharma producers and laboratories with equipment for contamination control and sterile processing. While this part of the portfolio may be smaller than hospital-focused units, it provides exposure to trends in biological research, vaccine production and advanced therapies. For investors, this diversification means that Getinge’s revenue is not solely tied to public hospital budgets but also benefits from research funding and private sector biopharma investments. However, this also brings additional regulatory and quality management requirements, as life science customers operate under stringent standards for contamination control and reproducibility.

Across all these segments, Getinge’s business model typically combines one-off equipment sales with long-term service contracts, spare parts supply and consumables. This combination can create a large installed base of equipment across hospitals worldwide, which then drives recurring revenue for maintenance, upgrades and training. From an equity perspective, this installed base can be considered a strategic asset, because it often leads to repeat business when hospitals renew equipment or expand capacity. It also means that Getinge’s performance is closely linked to utilization levels in hospitals, because higher procedure volumes often translate into growing demand for service and consumables.

Another component of the business model is compliance with regulatory standards and medical device approvals in various jurisdictions. Products such as intensive care ventilators, cardiovascular devices or sterilization systems need certification and surveillance by regulators in Europe, the United States and other regions. This creates barriers to entry for smaller competitors but also requires substantial investments in quality management, clinical evaluation and post-market surveillance. Getinge therefore allocates part of its resources to regulatory and compliance functions, which can influence profitability but also protect the franchise in critical product categories.

Main revenue and product drivers for Getinge AB

In recent years, Getinge’s revenue mix has been shaped by a combination of intensive care equipment demand, surgical infrastructure projects and continued needs in infection control. During and after the COVID-19 pandemic, ventilator and critical care equipment demand experienced a surge, but management has since communicated that the market has gradually normalized. This shift was discussed in company presentations around 2023 and 2024, where the focus moved from emergency orders towards replacement demand and technology upgrades in intensive care units (Getinge news overview as of 11/15/2024). As a result, growth prospects increasingly depend on broader hospital investment cycles rather than extraordinary crisis-related orders.

Within the acute care therapies area, ventilators, advanced monitoring and cardiovascular devices typically account for a substantial share of revenue. These products are often used in high-acuity settings, which means that hospitals can be reluctant to switch suppliers frequently due to staff training and interoperability considerations. Additionally, software and connectivity functions are becoming more important revenue drivers, as hospitals look to integrate intensive care equipment into broader data platforms. Getinge has highlighted digitalization and connected solutions as strategic priorities in its communication with investors, noting that this can also support recurring software revenue and service contracts, according to investor presentation themes in 2024 (Getinge capital markets material as of 06/12/2024).

Surgical workflows represent another significant revenue pillar. Here, major projects can lead to meaningful revenue swings between quarters, as large hospital construction or modernization projects are recognized. Operating room tables, lights, integration systems and sterile supply equipment often come as part of bundled solutions, which may include planning services and long-term maintenance agreements. For this reason, Getinge’s order intake in surgical workflows can be an early indicator of future revenue, and management typically comments on major orders and tender outcomes in quarterly reports and presentations. The extent to which hospitals prioritize elective surgery capacity, catch up on postponed procedures and expand infrastructure therefore has a direct impact on this segment.

Infection control products, including sterilizers and washer-disinfectors, are essential for both surgical departments and central sterile supply units. These systems must operate reliably, because downtime can disrupt operating room schedules. Getinge’s installed base and service network provide recurring revenue opportunities through preventive maintenance, spare parts and modernization packages. While competition exists from other specialized equipment manufacturers, the combination of equipment performance, service coverage and integration with workflow software is often a key differentiator when hospitals decide on suppliers.

The life science segment, while smaller than the hospital-focused units, contributes to a more diversified revenue base. Equipment for contamination control and sterile processing is used by biopharmaceutical companies, vaccine producers and research labs, whose investment cycles differ from those of public hospitals. For example, a period of strong funding for biotech research or vaccine development can result in higher order intake in life science equipment. Conversely, a slowdown in biopharma capital expenditure can weigh on demand. Getinge’s exposure to this segment means that investors need to follow both healthcare policy and broader trends in pharmaceutical research and manufacturing.

Geographically, Europe and North America are core markets, but emerging regions also play a growing role. Hospitals in developing markets may still be building basic intensive care capacity and modernizing operating rooms, which can translate into multi-year growth opportunities. However, such projects often depend on public funding, multilateral development loans and currency stability. For a Swedish exporter like Getinge, currency movements between the Swedish krona and major currencies such as the US dollar and euro can influence reported revenue and margins. This is frequently highlighted in management’s commentary on foreign exchange effects in annual and quarterly reports.

Another important revenue driver is service and aftermarket sales. Once equipment is installed, hospitals usually sign service contracts that cover preventive maintenance, repairs, calibration and software updates. These contracts can last for several years and provide a more predictable revenue stream compared with one-off equipment sales. In addition, hospitals may purchase consumables, accessories and upgrades over the lifetime of the equipment, further increasing the value of each installed unit. Investors often pay particular attention to the share of recurring revenue in Getinge’s mix, because a higher proportion can indicate more resilience during periods of muted capital spending.

Industry trends and competitive position

Getinge operates in a global medical technology industry that is shaped by demographic change, advances in surgical techniques and ongoing pressure on healthcare budgets. Aging populations in Europe, North America and parts of Asia are leading to rising demand for cardiovascular procedures, intensive care and complex surgeries. This trend supports structural demand for equipment used in operating rooms and intensive care units. At the same time, healthcare payers and hospital operators place strong emphasis on cost-efficiency and value-based care, which means suppliers need to demonstrate not only clinical effectiveness but also workflow efficiency and total cost of ownership benefits.

The competitive landscape includes large diversified medical technology groups and more specialized players in areas such as surgical equipment, sterilization and intensive care. In this environment, Getinge aims to differentiate through a combination of deep clinical expertise, broad product portfolios and integrated solutions. For example, the ability to offer a complete operating room setup including tables, lights, integration systems and sterile workflow management software can be an advantage compared with suppliers that offer only individual components. Moreover, long-standing relationships with hospitals and clinicians can help the company stay close to customer needs and co-develop new solutions that reflect real-world constraints.

Regulation and quality assurance are central to competitive dynamics. Medical device regulations in Europe and the United States have become more demanding, requiring extensive clinical data, post-market surveillance and risk management. While this increases compliance costs, it also raises barriers to entry for smaller companies without the resources to maintain complex regulatory systems. Getinge, as an established player, invests in quality and regulatory capabilities, which can support its long-term license to operate. Nevertheless, past industry experience has shown that quality issues or product recalls can significantly affect reputation and financial performance, so investors closely monitor company disclosures on quality and compliance initiatives.

Digitalization is another major trend shaping competition. Hospitals increasingly require equipment that can integrate into electronic health record systems, deliver data for clinical decision support and enable remote monitoring and diagnostics. Getinge has identified digital solutions, connectivity and data-driven services as growth areas in its strategy presentations. Examples include platforms that collect and analyze data from ventilators and other intensive care devices, helping clinicians optimize care protocols. This shift toward software and data services can potentially raise switching costs for customers and create new recurring revenue streams, but it also exposes the company to competition from technology-focused entrants and requires sustained investment in software development and cybersecurity.

From an ESG perspective, investors pay attention to how medical technology suppliers manage environmental impact, social responsibility and governance standards. For Getinge, this includes issues such as energy efficiency of equipment, responsible sourcing, product lifecycle management and access to healthcare. The company has published sustainability targets and reports that outline its ambitions in reducing climate impact and enhancing social contributions, which are discussed in its sustainability reports and investor communications (Getinge sustainability information as of 03/20/2024). For institutional investors with ESG mandates, these aspects can be a material component of the investment thesis.

Why Getinge AB matters for US investors

Even though Getinge AB is listed on Nasdaq Stockholm and reports in Swedish krona, the company has a significant presence in North America through sales of intensive care equipment, surgical workflow solutions and life science products. For US-focused investors who track global healthcare suppliers, Getinge offers exposure to hospital and research spending trends that complement US-listed peers. In particular, the company’s installed base in US hospitals means that its performance can be influenced by factors such as Medicare reimbursement policies, private insurer behavior and capital expenditure plans of major hospital systems.

US investors may also view Getinge as part of the broader ecosystem around surgical and intensive care procedures, which includes device manufacturers, hospital operators and healthcare IT providers. Because Getinge’s products are used in high-acuity settings, changes in procedure volumes and hospital occupancy rates can have a direct impact on demand for its equipment and services. As the US healthcare system continues to adapt to demographic change, shifts in care delivery models and post-pandemic capacity planning, global suppliers like Getinge can be affected in ways that complement or contrast with domestic US players. Monitoring the company’s disclosures on North American revenue and order trends can therefore provide additional context for sector-wide investment decisions.

Currency dynamics add another layer of consideration for US-based investors. Fluctuations between the US dollar and the Swedish krona can influence both reported results and the value of the investment when converted into dollars. Some investors may view this as a form of geographic and currency diversification within a healthcare allocation, while others may see it as an additional source of volatility. As always with non-US listings, practical aspects such as trading hours, liquidity on the home exchange and access via US broker platforms also play a role. Nevertheless, for investors who are comfortable analyzing European mid- to large-cap stocks, Getinge can function as a proxy for global hospital investment trends.

What type of investor might consider Getinge AB – and who should be cautious?

Getinge AB may attract investors who are interested in the defensive characteristics often associated with healthcare but who are also comfortable with exposure to capital equipment cycles. The company’s focus on intensive care, surgical workflows and infection control touches on areas that are essential for hospital operations, which can provide a degree of structural demand. Investors who appreciate business models with recurring service and consumable revenue alongside high-value equipment sales may find the structure of Getinge’s revenue mix noteworthy. Additionally, those who seek diversification away from purely US-listed healthcare names into European markets could view the stock as a complementary holding within an international medtech allocation.

On the other hand, more cautious investors might focus on risks related to regulatory requirements, product quality and capital spending volatility. Medical technology companies are exposed to potential product recalls, changes in regulatory frameworks and shifts in hospital purchasing behavior. For Getinge, large project-based orders in surgical workflows and infrastructure can also lead to fluctuations in quarterly figures, which may not suit investors seeking extremely stable short-term earnings patterns. Furthermore, currency risk arising from the Swedish krona’s movements against the US dollar can add an additional layer of complexity for investors who measure returns in dollars and do not hedge currency exposure.

Conclusion

Getinge AB combines exposure to critical hospital infrastructure, intensive care and life science applications in a single European-listed medical technology group. The company’s latest quarterly figures and strategy communications underline its dependence on hospital investment cycles, service revenues and ongoing demand for infection control and surgical workflows. At the same time, the focus on digitalization, connectivity and sustainability reflects broader industry trends that could reshape competitive dynamics over the coming years. For US investors looking beyond domestic markets, Getinge offers a window into global hospital spending and medtech innovation, but the stock also carries typical sector risks such as regulatory requirements, project-based revenue volatility and currency effects. As with any individual equity, a balanced assessment will weigh these opportunities and uncertainties in the context of overall portfolio objectives.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.